PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Lung Cancer10.1016/s0169-5002(03)92593-1200341S250P-626 An epidemiological survey for interstitial lung disease induced by gefitinib in patients with advanced non-small cell lung cancerKoji Takeda, Nobuyuki Yamamotohttps://api.elsevier.com/content/article/PII:S0169500203925931?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500203925931?httpAccept=text/plain
Cancer Research and Treatment10.4143/crt.2014.201201648188-97Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer PatientsSeung-Hoon Beom, Dong-Wan Kim, Sung Hoon Sim, Bhumsuk Keam, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Dae Seog Heohttp://e-crt.org/upload/pdf/crt-2014-201.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2014.201, http://www.e-crt.org/upload/pdf/crt-2014-201.pdf
Clinical Lung Cancer10.1016/j.cllc.2013.12.0042014153e33-e35Successful Crizotinib Rechallenge After Crizotinib-Induced Interstitial Lung Disease in Patients With Advanced Non–Small-Cell Lung CancerNobuhiro Asai, Etsuro Yamaguchi, Akihito Kubohttps://api.elsevier.com/content/article/PII:S1525730413002611?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730413002611?httpAccept=text/plain
Lung Cancer10.1016/j.lungcan.2006.02.0022006522135-140Imaging of gefitinib-related interstitial lung disease: Multi-institutional analysis by the West Japan Thoracic Oncology GroupMasahiro Endo, Takeshi Johkoh, Kazuhiko Kimura, Nobuyuki Yamamotohttps://api.elsevier.com/content/article/PII:S0169500206001073?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500206001073?httpAccept=text/plain
Lung Cancer10.1016/j.lungcan.2003.09.0162004433367-368Severe acute interstitial pnuemonia and gefitinibKate Sumpter, Jo Congleton, Catherine Harper-Wynne, Mary O’Brienhttps://api.elsevier.com/content/article/PII:S0169500203005087?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500203005087?httpAccept=text/plain
Lung Cancer10.1016/j.lungcan.2004.01.010200445193-104Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinibToshimi Takano, Yuichiro Ohe, Masahiko Kusumoto, Ukihide Tateishi, Seiichiro Yamamoto, Hiroshi Nokihara, Noboru Yamamoto, Ikuo Sekine, Hideo Kunitoh, Tomohide Tamura, Tetsuro Kodama, Nagahiro Saijohttps://api.elsevier.com/content/article/PII:S0169500204000406?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500204000406?httpAccept=text/plain
Clinical Lung Cancer10.1016/j.cllc.2012.03.009201314155-61Gefitinib-Related Interstitial Lung Disease in Taiwanese Patients With Non–Small-Cell Lung CancerShih-Chieh Chang, Cheng-Yu Chang, Shu-Ju Chang, Mei-Kang Yuan, Yi-Chun Lai, Yu-Chang Liu, Cheng-Yu Chen, Li-Chiao Kuo, Chong-Jen Yuhttps://api.elsevier.com/content/article/PII:S1525730412000769?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730412000769?httpAccept=text/plain
Lung Cancer10.1016/j.lungcan.2010.08.0122010702223-225Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicityGeoffrey Y. Ku, Akhil Chopra, Gilberto de Lima Lopeshttps://api.elsevier.com/content/article/PII:S0169500210003910?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500210003910?httpAccept=text/plain
Lung Cancer10.1016/s0169-5002(03)90500-9200341S112I-93. Gefitinib (“Iressa”): The patients' experienceGlen Gosshttps://api.elsevier.com/content/article/PII:S0169500203905009?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500203905009?httpAccept=text/plain
Lung Cancer10.1016/0169-5002(94)93901-219941133Interstitial hypertension in lung carcinomas in patientshttps://api.elsevier.com/content/article/PII:0169500294939012?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:0169500294939012?httpAccept=text/plain